Table 1.
Characteristics of the total patient sample (N = 149 262 [n = 65 620 men; n = 83 642 women]): A) Primary prevention group; B) secondary prevention group.
| A) CHARACTERISTICS | PRIMARY PREVENTION GROUP* | ||
|---|---|---|---|
|
| |||
| TOTAL NO. OF PATIENTS (N = 139 025), N (%) | MALE (N = 60 013), N (%) | FEMALE (N = 79 012), N (%) | |
| Taking statins | 5955 (4) | 3111 (5) | 2844 (4) |
| Not taking statins | 133 070 (96) | 56 902 (95) | 76 168 (96) |
| Age ≥ 75 y | 14 814 (11) | 6120 (10) | 8694 (11) |
| Taking statins and aged ≥ 75 y | 1374 (1) | 577 (1) | 797 (1) |
| Lipid testing in past 5 y | 32 950 (24) | 14 155 (24) | 18 435 (23) |
| Lipid testing inside age ranges | 23 736 (17) | 10 461 (17) | 13 275 (17) |
| Lipid testing and ≥ 75 y | 3528 (3) | 1299 (2) | 2229 (3) |
| Lipid testing while taking statins | 1596 (1) | 813 (1) | 756 (0) |
| B) CHARACTERISTICS | SECONDARY PREVENTION GROUP* | ||
|---|---|---|---|
|
| |||
| TOTAL NO. OF PATIENTS (N = 10 237), N (%) | MALE (N = 5607), N (%) | FEMALE (N = 4630), N (%) | |
| Taking statins | 3013 (29) | 1832 (32) | 1181 (26) |
| Not taking statins | 7224 (71) | 3775 (67) | 3449 (75) |
| Age ≥ 75 y | 5374 (52) | 2547 (45) | 2827 (61) |
| Taking statins and aged ≥ 75 y | 1472 (14) | 775 (14) | 697 (15) |
| Lipid testing in past 5 y | 4387 (43) | 2534 (45) | 1853 (40) |
| Lipid testing inside age ranges | 2288 (22) | 1477 (26) | 811 (18) |
| Lipid testing and aged ≥ 75 y | 2069 (20) | 1041 (19) | 1028 (22) |
| Lipid testing while taking statins | 911 (9) | 561 (10) | 350 (7) |
*
The 2016 Canadian Cardiovascular Society guidelines3 were followed for age cutoffs.